SPYPHARMA
0419.976.247 · rovalta.com · 23/09/2026
ACTIVE
SPYPHARMA
Financial year 2025 · closed on 31/12/2025
Net result
-147,8 k €
-131.9% YoY
Gross margin
229,2 k €
+71.9% YoY
Equity
-157,9 k €
-1465.1% YoY
Workforce
1,1 ETP
-42.1% YoY
Overview
What does SPYPHARMA do?
SPYPHARMA is a Private limited company incorporated in 1979. Its registered office is in Forest. It employs on average 1,1 ETP workers (FTE).
Legal situation
● Normal situation
BCE/KBO no. / VAT
BE 0419.976.247
Incorporation
05/12/1979
Legal form
Private limited company
Registered office
Rue des Châtaignes 21 box B
1190 Forest · BruxellesSee on map
1190 Forest · BruxellesSee on map
Contributed capital
18 592,01 €
Latest accounts
31/12/2025
Average workforce
1,1 ETP
Joint committees (2)
- 313
- 3130
Signals
Healthy social debts
Available with a Rovalta subscriptionTry for 7 days
Financials
Trend over 20 financial years
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||||||||||||||||||||||||||||||
| Gross margin | 229,2 k € | +71.9% | 133,3 k € | +1467% | 8,5 k € | -96.1% | 219,1 k € | -0.8% | 221 k € | +19.2% | 185,3 k € | +35.0% | 137,3 k € | +11.3% | 123,4 k € | -4.1% | 128,6 k € | +8.6% | 118,4 k € | +114% | 55,3 k € | -52.7% | 117,1 k € | +14.7% | 102 k € | +136% | 43,2 k € | -43.4% | 76,3 k € | -12.0% | 86,7 k € | -32.7% | 128,9 k € | +7.8% | 119,6 k € | +7.0% | 111,8 k € | -1.8% | 113,8 k € |
| EBITDA | -27,4 k € | -113% | -12,9 k € | -196% | -4,3 k € | -102% | 217,7 k € | +24.2% | 175,2 k € | +2.6% | 170,7 k € | +34.7% | 126,7 k € | +13.0% | 112,2 k € | -4.7% | 117,7 k € | +75.6% | 67 k € | +436% | -19,9 k € | -188% | 22,7 k € | -38.2% | 36,7 k € | +303% | -18,1 k € | +32.0% | -26,6 k € | -42.4% | -18,7 k € | -174% | 25,2 k € | +5.0% | 24 k € | +35.5% | 17,7 k € | -28.7% | 24,8 k € |
| Operating result | -97,3 k € | -159% | -37,6 k € | -92.8% | -19,5 k € | -110% | 203,1 k € | +23.2% | 164,8 k € | +2.0% | 161,5 k € | +37.0% | 117,9 k € | +14.1% | 103,3 k € | -7.1% | 111,2 k € | +72.5% | 64,5 k € | +391% | -22,2 k € | -211% | 20,1 k € | -40.7% | 33,8 k € | +270% | -19,9 k € | +31.1% | -28,8 k € | -40.1% | -20,6 k € | -199% | 20,8 k € | +3.9% | 20 k € | +48.0% | 13,5 k € | -21.7% | 17,2 k € |
| Net result | -147,8 k € | -132% | -63,7 k € | -66.4% | -38,3 k € | -120% | 188,4 k € | +23.0% | 153,2 k € | +1.9% | 150,4 k € | +1.4% | 148,3 k € | +38.8% | 106,8 k € | +191% | -116,9 k € | -272% | 67,9 k € | +323% | -30,4 k € | -270% | 17,9 k € | -20.2% | 22,5 k € | +167% | -33,4 k € | +12.4% | -38,1 k € | -47.6% | -25,8 k € | -350% | 10,3 k € | -60.3% | 26 k € | -21.2% | 33 k € | +62.7% | 20,3 k € |
| Balance sheet | |||||||||||||||||||||||||||||||||||||||
| Equity | -157,9 k € | -1465% | -10,1 k € | -119% | 53,6 k € | -41.7% | 91,9 k € | +2.7% | 89,5 k € | +1.0% | 88,6 k € | +0.4% | 88,2 k € | +84.0% | 47,9 k € | +181% | -58,9 k € | -202% | 58 k € | +687% | -9,9 k € | -148% | 20,5 k € | +17.8% | 17,4 k € | +446% | -5 k € | -118% | 28,4 k € | -57.3% | 66,5 k € | -28.0% | 92,3 k € | +12.6% | 82 k € | +46.4% | 56 k € | -54.5% | 123 k € |
| Total assets | 1,6 M € | +78.3% | 909,2 k € | +21.6% | 748 k € | -6.6% | 800,7 k € | +6.7% | 750,6 k € | +36.6% | 549,5 k € | +6.1% | 518 k € | +43.3% | 361,4 k € | -24.2% | 477,1 k € | -20.4% | 598,9 k € | +134% | 255,9 k € | -20.1% | 320,4 k € | +28.4% | 249,4 k € | -19.7% | 310,5 k € | +2.1% | 304,1 k € | -20.2% | 381 k € | +12.5% | 338,8 k € | +8.8% | 311,3 k € | -25.4% | 417 k € | +4.0% | 401,1 k € |
| Cash | 34,1 k € | -67.5% | 105 k € | +251% | 29,9 k € | +129% | 13,1 k € | +72.3% | 7,6 k € | -76.9% | 32,8 k € | -26.1% | 44,4 k € | +3.0% | 43,1 k € | -31.5% | 62,9 k € | -21.9% | 80,5 k € | +1896% | 4 k € | -86.7% | 30,4 k € | +21.9% | 25 k € | -54.7% | 55 k € | +38.3% | 39,8 k € | -18.8% | 49 k € | -14.3% | 57,1 k € | +30.8% | 43,7 k € | -21.9% | 55,9 k € | -9.3% | 61,6 k € |
| Debts | 1,8 M € | +93.5% | 919,3 k € | +32.5% | 693,7 k € | +0.3% | 691,4 k € | +10.4% | 626,4 k € | +41.9% | 441,4 k € | +4.3% | 423,3 k € | +35.8% | 311,6 k € | -41.8% | 535,7 k € | -0.9% | 540,5 k € | +116% | 250,4 k € | -15.4% | 296 k € | +28.3% | 230,6 k € | -26.8% | 315,1 k € | +14.6% | 274,9 k € | -12.5% | 314,3 k € | +27.6% | 246,4 k € | +7.6% | 228,9 k € | -36.0% | 357,6 k € | +28.6% | 278 k € |
| Other | |||||||||||||||||||||||||||||||||||||||
| Workforce | 1,1 ETP | -42.1% | 1,9 ETP | +850% | 0,2 ETP | – | – | – | – | – | – | 0,2 ETP | -88.9% | 1,8 ETP | -28.0% | 2,5 ETP | +31.6% | 1,9 ETP | -5.0% | 2,0 ETP | -31.0% | 2,9 ETP | -6.5% | 3,1 ETP | +3.3% | 3,0 ETP | 0.0% | 3,0 ETP | 0.0% | 3,0 ETP | 0.0% | 3,0 ETP | |||||||
Governance
Board of directors
Seen on filing of 31/12/2025 · 1 active · 7 ended
At this address
Other companies at this address
| Company | CBE no. |
|---|---|
ALEXARA● Active | 1023.674.256 |
CLAREXIS & CO● Active | 1002.062.656 |
DAVOINE● Active | 0471.519.572 |
PHARMACIE DAVOINE● Active | 0444.488.642 |
PHARMACIE DUFRANE● Active | 0477.954.434 |
Financials
Annual accounts
Full financial information
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Type of account | Abridged model | Abridged model | Abridged model | Abridged model | Abridged model | Abridged model |
| Start of the financial year | 01/01/2025 | 01/01/2024 | 01/01/2023 | 01/01/2022 | 01/01/2021 | 01/01/2020 |
| Closing of the financial year | 31/12/2025 | 31/12/2024 | 31/12/2023 | 31/12/2022 | 31/12/2021 | 31/12/2020 |
| Length of the financial year | 12 months | 12 months | 12 months | 12 months | 12 months | 12 months |
| Filing date | 30/08/2026 | 28/08/2025 | 27/09/2024 | 29/08/2023 | 30/09/2022 | 30/08/2021 |
| General meeting | 29/05/2026 | 30/05/2025 | 31/05/2024 | 26/05/2023 | 27/05/2022 | 28/05/2021 |
| Currency of the financial year | EUR | EUR | EUR | EUR | EUR | EUR |
| NBB quality label | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls |
Ratios
Financial ratios
Looking for more information about this company?
Try for 7 daysFilings
Annual accounts filings
20 filings with the NBB
| Model | Closing | General meeting | Filed | Language | Document |
|---|---|---|---|---|---|
| Abridged model | 31/12/2025 | 29/05/2026 | 30/08/2026 | French | |
| Abridged model | 31/12/2024 | 30/05/2025 | 28/08/2025 | French | |
| Abridged model | 31/12/2023 | 31/05/2024 | 27/09/2024 | French | |
| Abridged model | 31/12/2022 | 26/05/2023 | 29/08/2023 | French | |
| Abridged model | 31/12/2021 | 27/05/2022 | 30/09/2022 | French | |
| Abridged model | 31/12/2020 | 28/05/2021 | 30/08/2021 | French | |
| Abridged model | 31/12/2019 | 31/08/2020 | 29/09/2020 | French | |
| Abridged model | 31/12/2018 | 31/05/2019 | 29/08/2019 | French | |
| Abridged model | 31/12/2017 | 25/05/2018 | 29/08/2018 | French | |
| Abridged model | 31/12/2016 | 26/05/2017 | 29/08/2017 | French | |
| Abridged model | 31/12/2015 | 27/05/2016 | 08/09/2016 | French | |
| Abridged model | 31/12/2014 | 29/05/2015 | 02/06/2015 | French | |
| Abridged model | 31/12/2013 | 30/05/2014 | 01/08/2014 | French | |
| Abridged model | 31/12/2012 | 31/05/2013 | 05/08/2013 | French | |
| Abridged model | 31/12/2011 | 25/05/2012 | 21/06/2013 | French | |
| Abridged model | 31/12/2010 | 27/05/2011 | 31/08/2011 | French | |
| Abridged model | 31/12/2009 | 28/05/2010 | 31/08/2010 | French | |
| Abridged model | 31/12/2008 | 29/05/2009 | 25/06/2009 | French | |
| Abridged model | 31/12/2007 | 30/05/2008 | 28/08/2008 | French | |
| Abridged model | 31/12/2006 | 24/08/2007 | 28/08/2007 | French |
Valuation
Estimate
Indicative valuation
The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.
Disclaimer
Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.
Directors & structure
Publications
Belgian Official Gazette
Belgian Official Gazette publications
- Mandates15/10/2024DEMISSIONS, NOMINATIONS
- Mandates08/09/2022STATUTS (TRADUCTION, COORDINATION, AUTRES MODIFICATIONS, ) - MODIFICATION FORME JURIDIQUE - DENOMINATION - CAPITAL, ACTIONS - DEMISSIONS, NOMINATIONS
- Registered office01/07/2016SIEGE SOCIAL
- Mandates13/05/2016DEMISSIONS, NOMINATIONS
- Capital / shares17/11/2009CAPITAL, ACTIONS - STATUTS (TRADUCTION, COORDINATION, AUTRES MODIFICATIONS, )
Source: Belgian Official Gazette
Similar companies
Competition
Similar companies
A company's peers, by sector and size, are included in the Business plan.
See the Business planTimeline
Timeline
- 2025Annual accounts 2025-147,8 k €↓
- 2024Annual accounts 2024-63,7 k €↓
- 2023Annual accounts 2023-38,3 k €↓
- 2022Annual accounts 2022188,4 k €↑
- 2022Name changeSPYPHARMA
- 2021Annual accounts 2021153,2 k €↑
- 2021Name changePharmacie Thiry - Bronfort
- 2020Annual accounts 2020150,4 k €↑
- 2019Annual accounts 2019148,3 k €↑
- 2018Annual accounts 2018106,8 k €↑
- 2017Annual accounts 2017-116,9 k €↓
- 2016Annual accounts 201667,9 k €↑
- 2015Annual accounts 2015-30,4 k €↓
- 2014Annual accounts 201417,9 k €↓
- 2013Annual accounts 201322,5 k €↑
- 2012Annual accounts 2012-33,4 k €↑
- 2011Annual accounts 2011-38,1 k €↓
- 2010Annual accounts 2010-25,8 k €↓
- 2009Annual accounts 200910,3 k €↓
- 2008Annual accounts 200826 k €↓
- 2007Annual accounts 200733 k €↑
- 2006Annual accounts 200620,3 k €
- 05/12/1979IncorporationPrivate limited company